245 First Street - 18th Floor
Fax: 617- 444-8405
About GENFIT CORP.Genfit is a biopharmaceutical company, listed on Alternext by Euronext™ Paris (ALGFT - FR0004163111) with headquarters in Lille, France and a US subsidiary in Cambridge, Massachusetts.
Through its world-renowned scientific expertise, particularly in the field of nuclear receptors, Genfit’s research efforts are focused on the discovery and development of new treatments mainly in the growing therapeutic areas of Cardiometabolic and Neurodegenerative disorders, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer’s. Genfit uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health problems and their unmet medical needs.
Genfit has an original business model built on both proprietary internal programs and a strong track record of partner-supported programs and collaborations. This strategy allows the company to efficiently manage the risks associated with the internal programs, and at the same time build value for its shareholders. Genfit, on its own or in collaboration with its major pharmaceutical partners, has thus created a rich and diversified pipeline of drug candidates in pre-clinical and clinical development, as well as a broad intellectual property portfolio.
Genfit’s strong portfolio of therapeutic products, tools, and clinical biomarkers, together with its scientific expertise, have made the Company into a European biotechnology leader.
Parc Eurasanté – Lille Metropole
885 Avenue Eugene Avinee
Tel : +33 (0)3 2016 4000
Fax : +33 (0)3 2016 4001
175 articles with GENFIT CORP.
10/1/2020Biopharma and life sciences companies from across the globe provide updates on their pipelines and business practices.
8/6/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
7/27/2020It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.
Following negative interim data from its experimental treatment for non-alcoholic steatohepatitis (NASH) and fibrosis, France’s GENFIT will discontinue the Phase III RESOLVE-IT study of elafibranor in this indication.
7/10/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
5/18/2020Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.
5/14/2020Biopharma and life sciences companies from across the globe provide updates on their pipeline and business.
They expect to share the complete findings with regulators in the upcoming months and make a final decision on whether to continue the clinical trial.
4/2/2020Biopharma companies from across the globe provide updates on their pipelines and business practices.
GENFIT: Positive 42-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH
Data Safety Monitoring Board (DSMB) recommends the continuation of the RESOLVE-IT clinical trial without any modifications, based on the pre-planned review of safety data
11/18/2019It was a busy week for clinical trial announcements. Here’s a look.
GENFIT, a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, announces its first half 2019 financial results.
GENFIT announced Dr. Dean Hum’s appointment as President of GENFIT Corp. and Dr. Suneil Hosmane as Head of Global Diagnostics.
GENFIT announced that Dr. Carol L. Addy has joined the Company as Chief Medical Officer.
9/6/2019Biopharma companies strengthen the C-suite and board of directors with these appointments.
GENFIT: Board of Directors, Represented by Chairman Jean-François Mouney, Appoints Pascal Prigent as New CEO
GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, today announced that its board of directors has appointed Pascal Prigent, GENFIT’s Executive Vice President of Marketing and Commercial Development, as Chief Executive Officer, following the recommendation of Jean-François Mouney, who will remain Chairman of the Board.
6/27/2019Biotech and pharma companies from across the globe share pipeline and business updates.
GENFIT and Terns Pharmaceuticals Announce $228MM Strategic Partnership to Develop and Commercialize Elafibranor in Greater China
GENFIT announced the signing of a licensing and collaboration agreement with Terns Pharmaceuticals, a global biopharmaceutical company based in the U.S. and China with a focus on developing novel and combination therapies to treat liver disease.
GENFIT announced the results of the voting by shareholders at the Ordinary Shareholders’ Meeting which took place on June 13, 2019, in Lille, France.
A year ago, GENFIT gathered an international coalition to support The NASH Education Program and launch the 1st successful edition of International NASH Day